German Cannabis Legalization Rollback: June 30, 2026 Update
German state interior ministers are moving to roll back federal cannabis legalization despite supporting evidence, potentially disrupting implementation and patient access. This policy shift reflects broader tensions between regulatory frameworks and…
Policy Watch: 20 Regulatory Updates — June 22, 2026
Policy WatchJune 22, 2026. 20 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score. Score 70Federal RegisterSchedules of…
Schedules of Controlled Substances: Rescheduling FDA-Approved Marijuana Products
The DEA rescheduling Schedule III cannabis marks a pivotal regulatory change for FDA approved cannabis products. This shift facilitates improved medical cannabis access under federal law. Clinicians and patients should understand the implications of this…
Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register cannabis policyDEA schedulingcontrolled substancesSchedule I…
Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
The DEA has issued temporary scheduling orders placing 2-fluorodeschloroketamine into Schedule I. These orders address emerging synthetic drugs and their regulatory challenges. Temporary scheduling orders are critical for managing novel substances with…
Policy Watch: 20 Regulatory Updates — June 21, 2026
Policy WatchJune 21, 2026. 20 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score. Score 70Federal RegisterSchedules of…
International Cannabis Policies and Their Association with Cannabis Use, Cannabis Use Disorder, and Other Psychiatric Disorders
International cannabis policies shape cannabis use and cannabis use disorder prevalence worldwide. Commercialized legalization is linked to increased cannabis use disorder rates. However, associations with broader psychiatric disorders remain…
Policy Watch: 20 Regulatory Updates — June 19, 2026
Policy WatchJune 19, 2026. 20 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score. Score 70Federal RegisterSchedules of…
Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register cannabis policycannabis lawfederal cannabisstate regulationDEA…
Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register cannabis policycannabis lawfederal cannabisstate regulationDEA…